104795-85-9

Basic information

• Product Name: Methyl 6-chlorobenzo[b]thiophene-2-carboxylate
• Synonyms: Methyl 6-chlorobenzo[b]thiophene-2-carboxylate;Methyl 6-chloro-1-benzothiophene-2-carboxylate, 6-Chloro-2-(methoxycarbonyl)benzo[b]thiophene;6-Chloro-benzo[b]thiophene-2-carboxylic acid methyl ester
• CAS NO: 104795-85-9
• Molecular Formula: C10H7ClO2S
• Molecular Weight: 226.67938
• Mol File: 104795-85-9.mol
• Article Data: 9

Chemical Properties

• Melting Point: 107-109
• Boiling Point: 338.7°C at 760 mmHg
• Flash Point: 158.6°C
• Appearance: /
• Density: 1.391g/cm³
• Vapor Pressure: 9.66E-05mmHg at 25°C
• Refractive Index: 1.646
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Methyl 6-chlorobenzo[b]thiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-chlorobenzo[b]thiophene-2-carboxylate(104795-85-9)
• EPA Substance Registry System: Methyl 6-chlorobenzo[b]thiophene-2-carboxylate(104795-85-9)

Safety Data

• Hazardous Substances Data: 104795-85-9(Hazardous Substances Data)

Usage

General Description

Methyl 6-chlorobenzo[b]thiophene-2-carboxylate is an organic compound with the molecular formula C12H9ClO2S. It is a chlorinated benzo[b]thiophene derivative with a methyl ester functional group. This chemical is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has potential applications in the field of medicinal chemistry due to its ability to form derivatives with biological activity. Additionally, it can be used as a building block for the development of new compounds with diverse properties and applications. Methyl 6-chlorobenzo[b]thiophene-2-carboxylate is also used in research and development processes in the pharmaceutical and agrochemical industries.

InChI:InChI=1/C10H7ClO2S/c1-13-10(12)9-4-6-2-3-7(11)5-8(6)14-9/h2-5H,1H3

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 1301265-08-6 2-gem-dibromovinyl-5-chlorobenzothiol 
• 5551-11-1 4-Chloro-2-nitrobenzaldehyde 
• 2365-48-2 Methyl thioglycolate 
• 61072-56-8 4-chloro-2-fluorobenzaldehyde 
• 21211-18-7 3,6-dichloro-benzo[b]thiophene-2-carboxylic acid methyl ester 

Downstream Products

• 26018-73-5 6-chlorobenzo[b]thiophene-2-carboxylic acid 

Relevant articles and documents

Axially chiral 3,3′-bi(1-benzothiophene)-2,2′-dicarboxylic acid and its derivatives

Ullmann dimerization of substituted methyl 3-X-1-benzothiophene-2-carboxylates 1-7 (X = Cl, Br) gave rise to the corresponding dimeric 3,3′-bi(1-benzothiophene) esters 8-13. Resolution of the title acid 20 by fractional crystallization of its mono- and bisquininium salt afforded pure (R)- and (S)-enantiomers, the optical purity and absolute configuration of which was confirmed by CD spectrometry and by X-ray crystallography. Ullmann dimerization of chiral oxazolines 23 and 24 derived from 2 proceeded without any diastereodifferentiation. Reduction of (R)- and (S)-20 afforded the corresponding (R)- and (S)-diols 29, which served as chiral ligands in a model enantioselective reduction of acetophenone. (R)- and (S)-1-phenylethan-1-ol were formed in 28 and 29% e.e., respectively.

Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents

To discover antifungal compounds with broad-spectrum and stable metabolism, a series of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives was designed and synthesized. Compounds A30-A34 exhibited excellent broad-spectrum antifungal activity against Candida albicans with MIC values in the range of 0.03–0.5 μg/mL, and against Cryptococcus neoformans and Aspergillus fumigatus with MIC values in the range of 0.25–2 μg/mL. In addition, compounds A31 and A33 showed high metabolic stability in human liver microsomes in vitro, with the half-life of 80.5 min and 69.4 min, respectively. Moreover, compounds A31 and A33 showed weak or almost no inhibitory effect on the CYP3A4 and CYP2D6. The pharmacokinetic evaluation in SD rats showed that compound A31 had suitable pharmacokinetic properties and was worthy of further study.

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.